Ganitumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Ganitumab
Monoclonal antibody
Type Whole antibody
Source Human
Target IGF-1R
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
Formula C6472H10028N1728O2020S42
Molar mass 145.7 kg/mol
 NYesY (what is this?)  (verify)

Ganitumab a human monoclonal antibody against type 1 insulin-like growth factor receptor (IGF1R), designed for the treatment of cancers.[1]

Ganitumab was developed by Amgen. A phase III clinical trial (for metastatic pancreatic cancer) was abandoned in August 2012.[2][3]

References[edit]

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ganitumab" (PDF). American MedicaAssociation. 
  2. ^ "Amgen Pulls Cancer Drug". 10 Aug 2012. Archived from the original on 2013-07-23. 
  3. ^ "Amgen (AMGN) Terminates Ganitumab Pancreatic Cancer Trial". 8 Aug 2012. Archived from the original on 2012-08-10.